HYB timeline
Every HYB batch the index holds, newest manufacture date first, with the supplier's declared purity beside the median of the index's independent observations of the same lot.
| Lot | Compound | Manufactured | Quarter | Tests | Independent median | Spread (pp) | COA purity | Divergence (pp) | |
|---|---|---|---|---|---|---|---|---|---|
| HYB-2608-E4394 | CJC-1295 with DAC | 02 Aug 2026 | 2026-Q3 | 2 | 99.57 | 0.70 | 99.09 | -0.48 | |
| HYB-2606-D4861 | MOTS-c | 18 Jun 2026 | 2026-Q3 | 8 | 99.69 | 0.66 | 99.89 | +0.20 | |
| HYB-2604-D3661 | Retatrutide | 15 Apr 2026 | 2026-Q2 | 15 | 98.44 | 1.63 | 98.05 | -0.39 | |
| HYB-2603-U4136 | Epitalon | 16 Mar 2026 | 2026-Q2 | 10 | 99.70 | 0.72 | 99.90 | +0.20 | |
| HYB-2601-N5184 | Larazotide acetate | 20 Jan 2026 | 2026-Q1 | 8 | 99.70 | 0.42 | 99.70 | 0.00 | |
| HYB-2512-P5028 | BPC-157 | 30 Dec 2025 | 2026-Q1 | 1 | 99.93 | n<2 | 99.90 | -0.03 | |
| HYB-2512-W4240 | Tirzepatide | 12 Dec 2025 | 2026-Q2 | 8 | 98.81 | 0.57 | 98.80 | -0.01 | |
| HYB-2512-B4310 | Triptorelin | 02 Dec 2025 | 2026-Q1 | 4 | 99.36 | 0.41 | 98.50 | -0.86 | |
| HYB-2512-B3582 | SS-31 (Elamipretide) | 01 Dec 2025 | 2026-Q2 | 5 | 99.85 | 0.75 | 99.84 | -0.01 | |
| HYB-2511-P4320 | KPV | 24 Nov 2025 | 2026-Q1 | 1 | 99.33 | n<2 | 99.81 | +0.48 | |
| HYB-2511-F3454 | Semaglutide | 11 Nov 2025 | 2026-Q2 | 16 | 98.60 | 1.02 | 99.16 | +0.56 | |
| HYB-2511-R4907 | GHRP-6 | 03 Nov 2025 | 2025-Q4 | 14 | 99.86 | 0.26 | 99.90 | +0.04 | |
| HYB-2510-R4322 | Melanotan II | 31 Oct 2025 | 2026-Q1 | 10 | 99.80 | 0.34 | 99.90 | +0.10 | |
| HYB-2510-B4773 | CJC-1295 (no DAC) | 21 Oct 2025 | 2025-Q4 | 3 | 99.89 | 0.35 | 99.90 | +0.01 | |
| HYB-2510-H3125 | Semaglutide | 18 Oct 2025 | 2025-Q4 | 1 | 99.64 | n<2 | 99.90 | +0.26 | |
| HYB-2510-J4473 | Melanotan II | 17 Oct 2025 | 2026-Q1 | 1 | 99.42 | n<2 | 99.71 | +0.29 | |
| HYB-2510-J3407 | Enclomiphene citrate | 13 Oct 2025 | 2025-Q4 | 4 | 99.10 | 0.45 | 99.29 | +0.19 | |
| HYB-2509-W3468 | Retatrutide | 30 Sep 2025 | 2026-Q1 | 5 | 98.44 | 0.74 | 99.16 | +0.72 | |
| HYB-2509-K3969 | PT-141 (Bremelanotide) | 28 Sep 2025 | 2025-Q4 | 3 | 99.32 | 0.20 | 98.40 | -0.92 | |
| HYB-2509-J4106 | Tirzepatide | 21 Sep 2025 | 2026-Q1 | 6 | 98.45 | 1.32 | 99.21 | +0.76 | |
| HYB-2509-X4844 | MGF | 05 Sep 2025 | 2025-Q4 | 3 | 99.62 | 0.48 | 99.90 | +0.28 | |
| HYB-2508-R4525 | SS-31 (Elamipretide) | 30 Aug 2025 | 2026-Q1 | 2 | 99.82 | 0.11 | 99.90 | +0.08 | |
| HYB-2507-Y4488 | IGF-1 LR3 | 20 Jul 2025 | 2025-Q3 | 3 | 99.07 | 0.26 | 99.17 | +0.10 | |
| HYB-2507-A3589 | Tirzepatide | 07 Jul 2025 | 2025-Q3 | 14 | 99.89 | 0.29 | 99.90 | +0.01 | |
| HYB-2505-M3862 | MK-677 (Ibutamoren mesylate) | 22 May 2025 | 2025-Q2 | 1 | 99.85 | n<2 | 99.90 | +0.05 | |
| HYB-2504-X5304 | Survodutide | 26 Apr 2025 | 2025-Q3 | 14 | 98.75 | 0.94 | 98.84 | +0.09 | SHARED BULK |
| HYB-2504-N4251 | CJC-1295 (no DAC) | 03 Apr 2025 | 2025-Q3 | 10 | 99.26 | 0.91 | 99.62 | +0.36 | |
| HYB-2503-D4898 | Ipamorelin | 04 Mar 2025 | 2025-Q3 | 3 | 99.84 | 0.15 | 99.90 | +0.06 | |
| HYB-2502-S4617 | L-Glutathione (reduced) | 28 Feb 2025 | 2025-Q2 | 2 | 99.59 | 0.51 | 99.65 | +0.06 | |
| HYB-2502-G5280 | BPC-157 | 25 Feb 2025 | 2025-Q3 | 2 | 99.87 | 0.06 | 99.74 | -0.13 | |
| HYB-2502-R3188 | BPC-157 | 11 Feb 2025 | 2025-Q1 | 11 | 99.77 | 0.37 | 99.43 | -0.34 | |
| HYB-2501-T3293 | Dihexa | 09 Jan 2025 | 2025-Q2 | 5 | 99.78 | 0.41 | 99.90 | +0.12 | |
| HYB-2501-R4243 | GHRP-2 | 08 Jan 2025 | 2025-Q1 | 9 | 99.64 | 0.38 | 99.00 | -0.64 | |
| HYB-2410-J4560 | TB-500 | 27 Oct 2024 | 2025-Q1 | 5 | 99.93 | 0.35 | 99.53 | -0.40 | |
| HYB-2409-X3064 | BPC-157 | 14 Sep 2024 | 2024-Q4 | 9 | 98.46 | 0.41 | 99.08 | +0.62 | SHARED BULK |
| HYB-2408-W3304 | Tirzepatide | 15 Aug 2024 | 2025-Q1 | 10 | 99.07 | 1.20 | 99.53 | +0.46 | |
| HYB-2408-N4134 | Enclomiphene citrate | 13 Aug 2024 | 2024-Q4 | 6 | 99.92 | 0.43 | 99.90 | -0.02 | |
| HYB-2408-V4443 | Tirzepatide | 11 Aug 2024 | 2024-Q3 | 7 | 98.35 | 0.70 | 98.85 | +0.50 | SHARED BULK |
| HYB-2408-R4018 | Tirzepatide | 06 Aug 2024 | 2025-Q1 | 11 | 98.30 | 0.83 | 98.84 | +0.54 | |
| HYB-2407-J3695 | Exenatide | 29 Jul 2024 | 2024-Q3 | 13 | 98.73 | 1.32 | 98.50 | -0.23 | |
| HYB-2407-N4504 | GHRP-2 | 23 Jul 2024 | 2024-Q3 | 14 | 99.64 | 0.64 | 99.82 | +0.18 | |
| HYB-2407-V3438 | Semaglutide | 17 Jul 2024 | 2024-Q4 | 2 | 98.62 | 0.63 | 98.22 | -0.40 | |
| HYB-2407-N4370 | Hexarelin | 07 Jul 2024 | 2024-Q3 | 6 | 99.93 | 0.28 | 99.31 | -0.62 | |
| HYB-2407-W3597 | Retatrutide | 05 Jul 2024 | 2024-Q3 | 14 | 98.56 | 1.35 | 98.45 | -0.11 | |
| HYB-2405-C4633 | Selank | 10 May 2024 | 2024-Q2 | 14 | 99.81 | 0.57 | 99.77 | -0.04 | |
| HYB-2405-B3708 | CJC-1295 (no DAC) | 07 May 2024 | 2024-Q2 | 2 | 99.11 | 0.18 | 98.76 | -0.35 | |
| HYB-2403-B4304 | ARA-290 | 24 Mar 2024 | 2024-Q3 | 5 | 99.60 | 0.63 | 99.43 | -0.17 | |
| HYB-2403-C4990 | Humanin (HNG) | 02 Mar 2024 | 2024-Q2 | 10 | 99.67 | 0.69 | 99.66 | -0.01 |